Skip to content

SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs)

Ultracompact Hand-Held Swept-Source Optical Coherence Tomography (SS-HH-OCT) as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06177977
Acronym
SS-HH-OCT
Enrollment
80
Registered
2023-12-20
Start date
2024-03-01
Completion date
2026-12-31
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal Dystrophies

Keywords

Retinal dystrophy, Inherited retinal dystrophy, Early onset retinal dystrophies (EORDS)

Brief summary

The goal of this observational study is to utilize a novel imaging system designed for high-resolution retinal imaging of neonates, infants and children to identify the signs of photoreceptor development and degeneration in children with early-onset inherited retinal dystrophies (EORDs). Participants will have research imaging with SS-HH-OCT at the time of clinically-indicated eye examinations or procedures. The investigators aim to establish the basis for utilization of OCT imaging in earlier diagnosis and disease monitoring in children with EORDs. This work will set data reference standards and IRD endpoints that can be used in clinical trials.

Detailed description

What photoreceptor degenerative changes take place in children with early-onset inherited retinal dystrophies, and how is photoreceptor development in this patient population affected by genetic defects? Our novel investigational SS-HH-OCT system features high scanning speed, long laser wavelength, and an ergonomic light-weight handheld design. The investigators hypothesize that imaging with this system will enable us to characterize early-onset retinal dystrophies (EORD)-associated PDCs in young children. To this end, the investigators propose the following specific aims: Specific Aim 1: Optimize and demonstrate reproducibility of SS-HH-OCT imaging protocols to visualize photoreceptor development and degeneration in children with and without EORDs. Specific Aim 2: Use SS-HH-OCT parameters to characterize biomarkers of foveal photoreceptor development and degeneration in children with EORDs versus healthy controls. A total of 80 participants will be enrolled in this study. Participants' age between 0 through 8 years (\<9 years). For children with EORD, successful completion of this study will result in 1) a framework for reproducible OCT imaging; 2) characterization of biomarkers of retinal degeneration; 3) establishment of reference data by genetic variants 4) insights into foveal development. Additionally, this study will set pilot data of structure-function data and timeline of photoreceptor degeneration for future NIH funded studies.

Interventions

DEVICESS-HH-OCT

The investigational swept source OCT systems with handheld UC handpieces used in this study were developed at Duke University. OCT systems are non-contact, in-vivo optical imaging technology. The OCT system creates real-time, non-invasive images of ocular microstructure. OCT devices held above or in front of the eye while the sweeping infrared OCT beam scans across the retina. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are then stacked to create a volume; the stack may be summed up to create a retinal image. These retinal images are similar to images acquired during retinal photography except that they were captured with infrared light and provide depth information. Each volume and B-scan image can be viewed individually to measure and analyze ocular pathology.

Sponsors

Duke University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
0 Years to 8 Years
Healthy volunteers
Yes

Inclusion criteria

For all participants: * Participant's age is between 0 through 8 years (\<9 years) * Parent/legal guardian gives consents for the imaging study * No ocular media opacities that could preclude imaging * Refractive error equal or lower than 6 diopters For EORD participants (Groups 1-2): Meets clinical and molecular diagnosis of EORD (clinical determined by PI). Molecular diagnosis criteria: * Autosomal dominant gene: One pathogenic or likely pathogenic variant that meets the clinical phenotype * Autosomal recessive gene: two pathogenic or likely pathogenic variants in-trans which meet the phenotype. * X-linked gene: one pathogenic or likely pathogenic variant which meets the phenotype. For Controls (Group 3): No evidence of retinal pathology

Exclusion criteria

For all participants: * Parent/legal guardian unwilling or unable to provide consent * Refractive error higher than 6.00 diopters * Participant has media opacities that preclude imaging * Any non-IRD ocular condition that confound results interpretation such as glaucoma, uveitis, neurologic conditions affecting the optic nerve, etc. For EORD participants (Groups 1-2): Does not meet molecular diagnosis criteria For Controls (Group 3): Any suspicion of IRD

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with abnormal microanatomy as measured by OCT readingUp to 24 monthsPresence of abnormal retinal microanatomy as measured by OCT reading
Thickness of the participants retina at the fovea and surrounding optic nerve as measured by OCT readingUp to 24 monthsRetinal thickness (microns) at the fovea and surrounding optic nerve

Countries

United States

Contacts

Primary ContactRamiro Maldonado, MD
ramiro.maldonado@duke.edu(919) 684 5631
Backup ContactMichelle N McCall, MCAPM, BA
michelle.mccall@duke.edu(919) 684-0544

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026